Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
Investing.com -- Moderna shares jumped nearly 8% in premarket trading on Monday after a U.S. national tested positive for the Andes strain of hantavirus, drawing attention to the company’s early-stage work on a potential hantavirus treatment.
↗️ Moderna (MRNA): Shares jumped 8% premarket after the biomedical company told media outlets that it has been researching vaccines to protect against hantaviruses since before a recent cruise-ship outbreak.
The U.S. health department said one passenger on a repatriation flight has tested mildly positive for the virus, while another is currently experiencing mild symptoms.
Moderna shares rally as investors bet on recent Hantavirus outbreak accelerating the biotech firm’s path to profitability. But there are ample reasons to avoid buying MRNA stock today.
The stock has rapidly outpaced the broader market, but the long-term implications of the hantavirus are unclear.
Moderna reported positive Phase 3 results for its mRNA seasonal influenza vaccine candidate, mRNA-1010, showing stronger protection than the standard flu shot in a large adult study population. Regulatory submissions for mRNA-1010 are in progress in the US, Europe, Canada, and Australia, with the US FDA reviewing the data and an approval decision expected later this year. Separately, Moderna advanced its mRNA-based hantavirus vaccine collaboration with Korea University's Vaccine Innovation...
Evercore ISI analysts cautioned investors, writing Thursday that “with regards to current headlines, we see no meaningful revenue opportunity.”
Investing.com -- Moderna (NASDAQ:MRNA) shares climbed 10% on Thursday as concerns mounted over a hantavirus outbreak connected to a cruise ship.
Moderna (NASDAQ:MRNA) shareholders approved all four management proposals at the company’s 2026 Annual Meeting of Shareholders, including the re-election of two directors, advisory votes related to executive compensation, and the ratification of Ernst & Young as the company’s independent auditor
Moderna has notably outperformed the broader market over the past year, yet Wall Street analysts maintain a cautious outlook about the stock’s prospects.
Operational revenue from Pfizer’s Covid vaccine Comirnaty and Paxlovid pill to treat the illness declined 59% and 63%, respectively.
Raising capital while still building the data needed to validate an idea is often one of the biggest hurdles for start-ups.
Pfizer shares rose slightly in premarket trading after the company delivered a first-quarter earnings beat and reaffirmed its full-year outlook. The drugmaker posted adjusted earnings of 75 cents a share, ahead of the 72 cents Wall Street had forecast. Pfizer reaffirmed its full-year guidance, which it initially provided in December.
Health care stocks declined Monday afternoon, with the NYSE Health Care Index and the State Street H
Moderna (MRNA) is showing continued advancement across its pipeline, with progress in cancer vaccine
Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) just closed the books on Q4 2025, and the contrast is striking. Pfizer leaned on a diversified non-COVID portfolio and a fresh push into obesity drugs. Moderna leaned on cost cuts and international expansion to soften a steep COVID revenue cliff. Two very different pharma stories, both shaped by life ... Pfizer vs Moderna: Only One Pharma Giant Is a Winner In The Post-Covid Era
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
